Monoclonal and recombinant antibodies with T cell receptor-like reactivity

A Ziegler, PG Coulie, B Uchańska-Ziegler - Targeted Therapies in Cancer, 2007 - Springer
A Ziegler, PG Coulie, B Uchańska-Ziegler
Targeted Therapies in Cancer, 2007Springer
We will explain why major histocompatibility complex (MHC) molecules presenting peptides
derived from tumour-associated antigens can be recognized not only by T cell receptors
(TCR), but also by soluble proteins endowed with TCR-like reactivity. To understand how an
antibody can display high affinity and specificity for a particular MHC: peptide complex, we
have employed X-ray crystallography to determine the structure of a recombinant antibody,
Hyb3, bound to human HLA-A1 molecules presenting the peptide EADPTGHSY that is …
Abstract
We will explain why major histocompatibility complex (MHC) molecules presenting peptides derived from tumour-associated antigens can be recognized not only by T cell receptors (TCR), but also by soluble proteins endowed with TCR-like reactivity. To understand how an antibody can display high affinity and specificity for a particular MHC: peptide complex, we have employed X-ray crystallography to determine the structure of a recombinant antibody, Hyb3, bound to human HLA-A1 molecules presenting the peptide EADPTGHSY that is derived from the tumourassociated antigen MAGE-A1. The results indicate that although Hyb3 recgonizes its target in a TCR-like diagonal binding mode, important differences between the two types of proteins exist that are probably due to the fact that TCR are part of a molecular assembly on the surface of effector cells, while antibodies such as Hyb3 have to carry out their function as individual molecules.
Springer